PureTech Health

PRTC · Main Market · Health Care · mcap £262m · 111.0p

PureTech founds and part-owns biotech companies, developing some programmes itself before spinning them into separate 'Founded Entities' funded by outside investors. It earns returns through equity stakes, milestones and royalties.

Target	Promise	Said	Status
2023
31 Dec 2023	Provide guidance on capital allocation and returns strategy in Q4 2023	17 Oct 2023	✓ Kept
	“We plan to provide more guidance on our capital allocation and returns strategy in the fourth quarter.” Result December 2023 said the Board may declare special dividends or buybacks; $100m tender offer set out in March 2024. “The PureTech Board may declare special dividends and/or share buybacks as part of an overall returns strategy.”20 Dec 2023 · PRTC Year End Update & Outlook for 2024
2024
26 Sep 2024	KarXT FDA decision by PDUFA date of 26 September 2024	22 Dec 2023	✓ Kept
	“KarXT Is Expected to Launch in the U.S. for the Treatment of Schizophrenia in Adults with a Prescription Drug User Fee Act Date of September 26, 2024” Result FDA approved KarXT (Cobenfy) on 27 September 2024; PureTech received $29m milestones. 27 Sep 2024 · KarXT/Cobenfy Approved by FDA; PRTC Receives $29M
31 Dec 2024	Report Phase 2b ELEVATE IPF topline data for LYT-100 (deupirfenidone) by Q4 2024	11 Oct 2023	✓ Kept
	“Key catalysts expected in 2024 include results from idiopathic pulmonary fibrosis (IPF) late-stage trial of LYT-100 in Q4 2024.” Also stated 20 Dec 2023 Result Topline results announced 16 December 2024, meeting primary and key secondary endpoints. “The trial achieved its primary endpoint based on the prespecified Bayesian analysis, with a 98.5% posterior probability. This means there is a 98.5% probability that the pooled deupirfenidone arms were superior to placebo in slowing the rate of lung function decline in people with IPF, as measured by forced vital capacity (FVC) at 26 weeks. The trial also successfully demonstrated a dose-dependent response.”16 Dec 2024 · PRTC's Ph2b in IPF Successful; New SOC Potential
2025
31 Dec 2025	Report VE202 Phase 2 ulcerative colitis topline results in 2025	30 Apr 2025	✓ Kept
	“Vedanta anticipates topline results from its Phase 2b clinical trial of VE202 in ulcerative colitis in 2025” Result Results reported 13 August 2025, but the trial missed its primary endpoint. “today announced that its candidate VE202 did not meet the primary endpoint of endoscopic response in the Phase 2 COLLECTiVE202 study for the treatment of patients with mild-to-moderate ulcerative colitis (UC).”13 Aug 2025 · PRTC's Vedanta Announces VE202 Phase 2 Results “endoscopic and clinical responses were assessed using standardized criteria, and the observed response rates in the VE202 group were not statistically different from those in the placebo group.”13 Aug 2025 · PRTC's Vedanta Announces VE202 Phase 2 Results
Today · 10 Oct 2026
2026
31 Dec 2026	Seaport to start GlyphAgo Phase 2a trial in H2 2026	9 Jun 2026	✓ Kept
	“Seaport expects to initiate a Phase 2a proof-of pharmacology trial in the second half of 2026.” Result First patient dosed in Phase 2a on 7 October 2026. 7 Oct 2026 · PRTC's SPTX: Phase 2a Trial of GlyphAgo Initiated